Logo

CI

Cigna Corporation

CI

Cigna Corporation • NYSE
$277.46 ▼ -0.32% (-0.89)
Market Cap $74.12 B
52w High $350.00
52w Low $239.51
Dividend Yield 5.93%
P/E 12.28
Volume 550.00K
Outstanding Shares 267.13M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $69.748B ▲ $3.362B ▼ $1.868B ▲ 2.678% ▲ $7.02 ▲ $3.339B ▲
Q2-2025 $67.23B ▲ $5.454B ▲ $1.532B ▲ 2.279% ▲ $5.76 ▲ $3.04B ▼
Q1-2025 $65.502B ▼ $4.635B ▲ $1.323B ▼ 2.02% ▼ $4.88 ▼ $3.059B ▲
Q4-2024 $65.649B ▲ $4.289B ▲ $1.424B ▲ 2.169% ▲ $5.13 ▲ $2.941B ▼
Q3-2024 $63.694B $4.026B $739M 1.16% $2.65 $3.294B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.025B ▲ $157.919B ▲ $115.905B ▲ $41.805B ▲
Q2-2025 $5.142B ▼ $151.651B ▲ $111.221B ▲ $40.214B ▼
Q1-2025 $9.061B ▲ $150.658B ▼ $110.244B ▼ $40.226B ▼
Q4-2024 $8.215B ▲ $155.881B ▼ $114.638B ▼ $41.033B ▼
Q3-2024 $6.752B $157.639B $115.341B $42.095B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $1.868B ▲ $3.418B ▲ $-4.387B ▼ $2.659B ▲ $1.696B ▲ $3.14B ▲
Q2-2025 $1.632B ▲ $-1.886B ▼ $-797M ▼ $-1.333B ▲ $-3.99B ▼ $-2.171B ▼
Q1-2025 $1.409B ▼ $1.92B ▼ $1.197B ▲ $-3.681B ▼ $-555M ▼ $1.593B ▼
Q4-2024 $1.536B ▲ $5.212B ▲ $-191M ▲ $-3.248B ▼ $1.747B ▲ $4.875B ▲
Q3-2024 $825M $46M $-776M $439M $-273M $-353M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Cigna Healthcare
Cigna Healthcare
 $20.99Bn ▲$13.17Bn ▼$10.80Bn ▼$10.93Bn ▲
Evernorth
Evernorth
 $95.99Bn ▲$52.00Bn ▼$57.83Bn ▲$60.39Bn ▲

Five-Year Company Overview

Income Statement

Income Statement Cigna’s revenue has climbed steadily over the past five years, with a particularly strong step-up in the most recent year, showing that the core business is still expanding. However, profits have been more uneven. Operating profit has inched higher over time, but net income and earnings per share have swung around, ending the period below their earlier peaks. This suggests that while the underlying operations are solid, margins are under pressure and one‑off items, mix shifts, or pricing dynamics are weighing on the bottom line. Overall, it looks like a high‑volume business growing well on the top line, but fighting to translate that growth into consistently rising earnings for shareholders.

Balance Sheet

Balance Sheet The balance sheet is fairly steady and looks typical for a large health insurer and services company. Total assets have hovered in a similar range for several years, and cash levels are reasonable rather than excessive. Debt is meaningful but has not exploded higher, implying a measured use of borrowing. Equity has drifted down somewhat, which can reflect share buybacks and capital returns more than underlying stress. Taken together, Cigna appears neither over‑stretched nor overly conservative: it is running with a moderate level of leverage and a fairly stable financial base, but not an obviously “fortress” balance sheet.

Cash Flow

Cash Flow Cash generation is a relative bright spot. Operating cash flow has been consistently strong year after year, even in periods when accounting profits softened. Free cash flow stays comfortably positive after covering investment needs, and capital spending has been modest and predictable. This pattern points to a business that turns its revenue into real cash effectively, giving management flexibility to fund growth initiatives, pay down debt, or return capital. The main watchpoint is whether future profit volatility eventually spills over into weaker cash flow, but so far the cash profile looks resilient.

Competitive Edge

Competitive Edge Cigna’s competitive position leans heavily on its integrated model: traditional health benefits paired with the Evernorth services platform, which includes pharmacy benefit management, specialty pharmacy, and care solutions. This combination gives Cigna scale in drug spending, deep data on member health, and tools to manage costs for employers and health plans. Its broad provider network and focus on value‑based care help it push for better outcomes at lower cost, while its large base of “services‑only” employer relationships provides more stable, fee‑based revenue. On the flip side, the company competes in a very tough arena against giants like UnitedHealth and CVS/Aetna, and faces political and regulatory scrutiny, especially around pharmacy benefit practices and drug pricing. The moat looks real but constantly tested by regulation, competition, and changing buyer expectations.

Innovation and R&D

Innovation and R&D Cigna is leaning into digital health and analytics rather than traditional lab‑style R&D. Evernorth’s technology stack, virtual care offerings like MDLIVE, and tools such as AI‑powered assistants and personalized provider matching show a clear push toward data‑driven, always‑on care management. New programs like Pathwell, EncircleRx for GLP‑1 drug spending, and the use of biosimilars aim to tackle some of the fastest‑growing cost areas in healthcare. The venture arm, Cigna Ventures, broadens the innovation pipeline by investing in younger digital health and data companies. The opportunity is to turn these initiatives into better outcomes and cost control for clients; the risk is execution—integrating many moving parts, staying ahead of tech rivals, and navigating privacy and regulatory issues in an increasingly digital healthcare environment.

Summary

Taken together, Cigna looks like a scaled, strategically positioned healthcare player with a strong services backbone, steady balance sheet, and robust cash generation, but with profit volatility that tempers the otherwise solid growth story. Revenue growth and the Evernorth platform underscore a durable role in managing complex, high‑cost care, while digital tools and targeted programs suggest a thoughtful response to industry trends like specialty drugs, GLP‑1 therapies, and mental health. Key uncertainties center on margin pressure, regulatory and political risk—especially around pharmacy benefits and drug pricing—and the challenge of turning innovation into consistently rising earnings. The company appears built for the long haul in a changing healthcare system, but its path is unlikely to be smooth or free from policy and competitive shocks.

NEWS

November 25, 2025 · 9:00 AM UTC

Empire State Radiology Joins Cigna Network, Delivering Long-Term Access to Advanced Imaging for New Yorkers

Read more

November 12, 2025 · 6:00 AM UTC

The Cigna Group Announces Appearance at the 2025 UBS Global Healthcare Conference

Read more

November 10, 2025 · 6:00 AM UTC

Headspace for Cigna Healthcare Enhances Everyday Mental Health Support Through Self-Guided, Science Backed Resources

Read more

November 6, 2025 · 7:00 AM UTC

The Cigna Group Appoints Dr. Amy Flaster Chief Medical Officer

Read more

October 30, 2025 · 6:00 AM UTC

The Cigna Group Reports Strong Third Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook

Read more